Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) VP James M. Roach sold 1,091 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $13.67, for a total transaction of $14,913.97. Following the sale, the vice president now owns 156,056 shares in the company, valued at approximately $2,133,285.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 13.90 on Friday. Momenta Pharmaceuticals Inc. has a 12-month low of $7.86 and a 12-month high of $18.26. The company’s market capitalization is $958.50 million. The company’s 50 day moving average is $12.27 and its 200 day moving average is $11.65.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The business had revenue of $299.14 million for the quarter, compared to analyst estimates of $25.68 million. During the same quarter last year, the firm earned ($0.44) EPS. Momenta Pharmaceuticals’s quarterly revenue was up 2067.7% compared to the same quarter last year. Analysts expect that Momenta Pharmaceuticals Inc. will post ($1.16) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNTA. Pacad Investment Ltd. purchased a new position in Momenta Pharmaceuticals during the second quarter valued at $103,000. Jane Street Group LLC purchased a new position in Momenta Pharmaceuticals during the second quarter valued at $109,000. Dynamic Technology Lab Private Ltd purchased a new position in Momenta Pharmaceuticals during the second quarter valued at $109,000. Profund Advisors LLC purchased a new position in Momenta Pharmaceuticals during the third quarter valued at $121,000. Finally, Cornerstone Capital Management Holdings LLC. purchased a new position in Momenta Pharmaceuticals during the third quarter valued at $135,000. 81.62% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th. Barclays PLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Momenta Pharmaceuticals in a research note on Thursday, November 3rd. Cowen and Company reiterated a “hold” rating on shares of Momenta Pharmaceuticals in a research note on Sunday, August 7th. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 10th. Finally, Maxim Group reiterated a “sell” rating and issued a $6.00 price objective on shares of Momenta Pharmaceuticals in a research note on Thursday, November 3rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $16.10.

TRADEMARK VIOLATION NOTICE: “James M. Roach Sells 1,091 Shares of Momenta Pharmaceuticals Inc. (MNTA) Stock” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/25/james-m-roach-sells-1091-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

5 Day Chart for NASDAQ:MNTA

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.